The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Humira adalimumab | AbbVie Deutschland GmbH & Co. KG | Spondylitis, Ankylosing; Arthritis, Juvenile Rheumatoid; Uveitis; Colitis, Ulcerative; Psoriasis; Arthritis, Psoriatic; Crohn Disease; Arthritis, Rheumatoid | 🇪🇺 EU 2003-09-08 | Order → |
| Trudexa adalimumab | Abbott Laboratories Ltd. | Spondylitis, Ankylosing; Arthritis, Rheumatoid; Arthritis, Psoriatic; Crohn Disease | 🇪🇺 EU 2003-09-01 | Order → |
| Busilvex busulfan | Pierre Fabre Medicament | Hematopoietic Stem Cell Transplantation | 🇪🇺 EU 2003-07-09 | Order → |
| Forsteo teriparatide | Eli Lilly Nederland B.V. | Osteoporosis; Osteoporosis, Postmenopausal | 🇪🇺 EU 2003-06-10 | Order → |
| Aldurazyme laronidase | Sanofi B.V. | Mucopolysaccharidosis I | 🇪🇺 EU 2003-06-09 | Order → |
| Fuzeon enfuvirtide | Roche Registration GmbH | HIV Infections | 🇪🇺 EU 2003-05-27 | Order → |
| Bextra valdecoxib | Pharmacia - Pfizer EEIG | Arthritis, Rheumatoid; Osteoarthritis; Dysmenorrhea | 🇪🇺 EU 2003-03-27 | Order → |
| Valdyn valdecoxib | Pharmacia Europe EEIG | Osteoarthritis; Arthritis, Rheumatoid; Dysmenorrhea | 🇪🇺 EU 2003-03-27 | Order → |
| Valdyn (previously Kudeq) valdecoxib | Pfizer Limited | Arthritis, Rheumatoid; Osteoarthritis; Dysmenorrhea | 🇪🇺 EU 2003-03-27 | Order → |
| Ytracis yttrium [90Y] chloride | CIS bio international | Radionuclide Imaging | 🇪🇺 EU 2003-03-24 | Order → |
| Hepsera adefovir dipivoxil | Gilead Sciences Ireland UC | Hepatitis B, Chronic | 🇪🇺 EU 2003-03-06 | Order → |
| Levitra vardenafil | Bayer AG | Erectile Dysfunction | 🇪🇺 EU 2003-03-06 | Order → |
| Vivanza vardenafil | Bayer AG | Erectile Dysfunction | 🇪🇺 EU 2003-03-04 | Order → |
| Carbaglu carglumic acid | Recordati Rare Diseases | Amino Acid Metabolism, Inborn Errors; Propionic Acidemia | 🇪🇺 EU 2003-01-24 | Order → |
| Theryttrex yttrium [90Y] chloride | MDS Nordion S.A. | Radionuclide Imaging | 🇪🇺 EU 2003-01-07 | Order → |
| Zavesca miglustat | Advanz Pharma Limited | Gaucher Disease; Niemann-Pick Diseases | 🇪🇺 EU 2002-11-20 | Order → |
| Cialis tadalafil | Eli Lilly Nederland B.V. | Erectile Dysfunction | 🇪🇺 EU 2002-11-12 | Order → |
| Somavert pegvisomant | Pfizer Europe MA EEIG | Acromegaly | 🇪🇺 EU 2002-11-12 | Order → |
| Actraphane insulin human (rDNA) | Novo Nordisk A/S | Diabetes Mellitus | 🇪🇺 EU 2002-10-07 | Order → |
| Actrapid human insulin (rDNA) | Novo Nordisk A/S | Diabetes Mellitus | 🇪🇺 EU 2002-10-07 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.